| Literature DB >> 25372293 |
Nilay Dey1, Mala Sinha2, Shivali Gupta1, Mariela Natacha Gonzalez3, Rong Fang4, Janice J Endsley1, Bruce A Luxon2, Nisha Jain Garg5.
Abstract
In this study, we have utilized wild-type (WT), ASC-/-, and NLRP3-/- macrophages and inhibition approaches to investigate the mechanisms of inflammasome activation and their role in Trypanosoma cruzi infection. We also probed human macrophages and analyzed published microarray datasets from human fibroblasts, and endothelial and smooth muscle cells for T. cruzi-induced changes in the expression genes included in the RT Profiler Human Inflammasome arrays. T. cruzi infection elicited a subdued and delayed activation of inflammasome-related gene expression and IL-1β production in mφs in comparison to LPS-treated controls. When WT and ASC-/- macrophages were treated with inhibitors of caspase-1, IL-1β, or NADPH oxidase, we found that IL-1β production by caspase-1/ASC inflammasome required reactive oxygen species (ROS) as a secondary signal. Moreover, IL-1β regulated NF-κB signaling of inflammatory cytokine gene expression and, subsequently, intracellular parasite replication in macrophages. NLRP3-/- macrophages, despite an inability to elicit IL-1β activation and inflammatory cytokine gene expression, exhibited a 4-fold decline in intracellular parasites in comparison to that noted in matched WT controls. NLRP3-/- macrophages were not refractory to T. cruzi, and instead exhibited a very high basal level of ROS (>100-fold higher than WT controls) that was maintained after infection in an IL-1β-independent manner and contributed to efficient parasite killing. We conclude that caspase-1/ASC inflammasomes play a significant role in the activation of IL-1β/ROS and NF-κB signaling of cytokine gene expression for T. cruzi control in human and mouse macrophages. However, NLRP3-mediated IL-1β/NFκB activation is dispensable and compensated for by ROS-mediated control of T. cruzi replication and survival in macrophages.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25372293 PMCID: PMC4221042 DOI: 10.1371/journal.pone.0111539
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1IL-1β production in macrophages infected by T. cruzi.
(A–D) PMA-differentiated THP-1 mφs were incubated with T. cruzi trypomastigotes (cell: parasite ratio, 1∶3), Tc lysate (10 µg protein/106 cells) or LPS (100 ng/ml) for 3 h (A&C) and 18 h (B&D). In some experiments, ATP was added during last 30 min of incubation (C&D). IL-1β release in supernatants was determined by ELISA. (E–G) IL-1β contributes to parasite control in mφs. THP-1 mφs were incubated with SYTO®11-labeled T. cruzi in the presence or absence of anti-IL-1β antibody for 18 h. (E) SYTO®11 fluorescence as an indicator of parasite uptake (shown by arrows) was determined by using an Olympus BX-15 microscope equipped with a digital camera (magnification 40X). (F) Quantitative PCR analysis of parasite burden in infected mφs by using Tc18SrDNA-specific oligonucleotides (normalized to human GAPDH). (G) Addition of anti-IL-1β antibody depletes secreted IL-1β levels in T. cruzi-infected mφs. In all figures, data are representative of three independent experiments and presented as mean ± SD. Significance is shown by *normal versus infected and #treated/infected versus infected (*,#p<0.05, **,##p<0.01, and ***,###p<0.001).
Inflammasome-related differential gene expression in THP-1 macrophages in response to T. cruzi infection (± ATP) in comparison to normal controls.
|
|
|
| ||||||
| Gene name | ddCt log ratio | p value | Gene name | ddCt log ratio | p value | Gene name | ddCt log ratio | p value |
| CXCL1 | −4.10 | 0.000 | CXCL1 | −4.48 | 0.000 | ACTB | −2.41 | 0.002 |
| TNF | −2.86 | 0.000 | TNF | −3.68 | 0.000 | CXCL2 | −2.21 | 0.001 |
| NFKBIA | −2.46 | 0.000 | CXCL2 | −5.36 | 0.000 | PTGS2 | −4.73 | 0.020 |
| CXCL2 | −3.14 | 0.000 | NFKBIA | −3.24 | 0.000 | TNF | −0.82 | 0.028 |
| CIITA | 3.07 | 0.001 | TXNIP | 2.46 | 0.000 | CIITA | −1.68 | 0.037 |
| BCL2 | 0.95 | 0.005 | ACTB | −2.79 | 0.001 | NLRP3 | −0.65 | 0.051 |
| NFKB1 | −1.03 | 0.007 | RIPK2 | −1.99 | 0.001 | |||
| RIPK2 | −1.43 | 0.008 | NFKB1 | −1.25 | 0.002 | |||
| TXNIP | 1.56 | 0.007 | MAPK3 | 1.42 | 0.006 | |||
| MAPK1 | 0.79 | 0.010 | PSTPIP1 | 1.11 | 0.006 | |||
| PSTPIP1 | 1.03 | 0.010 | NLRP3 | −0.96 | 0.007 | |||
| B2M | 1.44 | 0.023 | BCL2 | 0.86 | 0.009 | |||
| SUGT1 | 0.86 | 0.026 | SUGT1 | 1.03 | 0.010 | |||
| TAB2 | 0.66 | 0.032 | PYCARD | 1.10 | 0.015 | |||
| CCL5 | −1.12 | 0.042 | IL1B | −1.75 | 0.018 | |||
| PEA15 | 0.57 | 0.043 | RPL13A | 0.78 | 0.025 | |||
| PYCARD | 0.86 | 0.049 | IRF1 | 0.78 | 0.034 | |||
| CCL2 | −2.92 | 0.053 | CCL2 | −2.92 | 0.053 | |||
| RPL13A | 0.65 | 0.056 | CCL5 | −1.06 | 0.053 | |||
The 96-well RT Profiler Human Inflammasome PCR Arrays (SA Biosciences/Qiagen) were probed in triplicate with cDNA from THP-1 macrophages infected with T. cruzi (Tc) for 3 h or 18 h (with or without ATP) as described in Materials and Methods. The Ct values from qPCR data were analyzed by using open source HTqPCR v.1.7 software package (v.2.13). All array data were normalized by Quantile method and filtered to exclude genes that exhibited Ct values>35. The relative expression level of each target gene in treated cells was calculated using the formula, fold change = 2-ΔΔCt, where ΔCt represents the Ct (sample) - Ct (control). LimmaCt in HT-qPCR package was employed for contrast analysis of all the groups included in experiment and identification of genes that were overall differentially expressed (p<0.05).
Figure 2Venn diagram of inflammasome-related differential gene expression in mφs infected with T. cruzi (±ATP).
THP-1 mφs were incubated with T. cruzi or LPS (± ATP treatment) as in Fig. 1. Total RNA was isolated, and cDNA was used as a template to probe the expression of 95 genes (including house-keeping genes) in the RT2 Profiler Inflammasome PCR Arrays. The differential mRNA level was captured by quantitative RT-PCR, normalized to housekeeping genes, and HTqPCR was employed to attain the statistically significant differential expression in treated- versus-control samples (Table 1 and Table S2). Shown are Venn diagrams of comparative analysis of gene expression in T. cruzi-infected mφs at 3 h versus 18 h (A), effect of ATP stimulus on gene expression at 3 h (B) and 18 h (C) pi, and comparative effect of ATP stimulus on gene expression in LPS-treated mφs at 3 h (D) and 18 h (E). Differential up-regulation (green) and down-regulation (red) of genes with respect to controls is presented. Genes presenting as red with green arrow in B–F showed decreased expression without ATP but were up-regulated by ATP treatment (and vice versa).
Ingenuity iReport analysis of inflammasome-related datasets in THP-1 macrophages infected by T. cruzi for 3 h or 18 h (± ATP).
| Pathways | Gene name | FoCus mols | P value |
|
| |||
|
| |||
| 1) Inflammatory responses/infection | ↓B2M, ↓BCL2, ↑CCL2, ↑CCL5, ↓CIITA, ↑CXCL1, ↑CXCL2, ↑NFKB1, ↑NFKB1A, ↓PYCARD, ↑RIPK2,↑TNF, ↓TXNIP | 13 | 5.91E-12–2.49E-04 |
| 1a. Recruitment of neutrophils/phagoCytes | ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓PYCARD, ↑RIPK2, ↑TNF | 7 | 2.77E-10 |
| 1b. Activation of leukoCyte/lymphoCytes | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↑NFKB1, ↑NFKB1A, ↓PYCARD, ↑TNF | 9 | 1.89E-07 |
| 2) Cell death of immune cells (decreased) | ↓B2M, ↓BCL2, ↑CCL2, ↑CCL5, ↓CIITA, ↑CXCL1, ↑CXCL2, ↓MAPK1, ↑NFKB1, ↑NFKB1A, ↓PEA15, ↓PYCARD, ↑RIPK2, ↓TAB2, ↑TNF, ↓TXNIP | 16 | 4.50E-10 |
| 2a. Macrophage cell death (decreased) | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↑NFKB1, ↑NFKB1A, ↓PYCARD, ↑TNF | 9 | 3.78E-13 |
|
| |||
| Decreases MPT, mitoChondrial swelling | ↓B2M, ↓BCL2, ↑NFKB1, ↓PYCARD, ↑TNF | 5 | 7.27E-08 |
|
| |||
|
| |||
| 1) Inflammatory responses/infection | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓IL1B, ↓IRF1,↑NFKB1, ↑NFKB1A, ↓NLRP3, ↑PTGS2, ↓PYCARD, ↑RIPK2,↑TNF, ↓TXNIP | 16 | 7.54E-14–1.79E-05 |
| 1a. Recruitment/migration of phagoCytes/neutrophils | ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓IL1B, ↑MAPK3, ↑NLRP3, ↓PYCARD, ↑RIPK2, ↑TNF | 9 | 7.69E-09 |
| 1b. Activation of lymphoCyte/leukoCytes | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↓IL1B, ↓IRF1, ↑NFKB1, ↑PTGS2, ↓PYCARD, ↑RIPK2 ↑TNF, ↓TXNIP | 12 | 3.44E-12 |
| 2) Cell death of immune cells/necrosis (decreased) | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓IL1B, ↓IRF1, ↑MAPK3, ↑NFKB1, ↑NFKB1A, ↑NLRP3, ↑PTGS2, ↓PYCARD, ↑RIPK2, ↑TNF, ↓TXNIP | 16 | 9.06E-17–1.99E-05 |
| 2a. Cell death of phagoCytes, myeloid cells (decreased) | ↓BCL2, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓IL1B, ↓IRF1, ↑NFKB1, ↑NFKB1A, ↓PYCARD, ↑TNF | 11 | 9.06E-17 |
|
| |||
| Decreased MPT, mitoChondrial swelling | ↓B2M, ↓BCL2, ↑NFKB1, ↓PYCARD, ↑TNF | 5 | 7.27E-08 |
|
| |||
|
| |||
| 1) Cell death of immune cells (decreased) | ↓ACTB, ↓CASP4, ↑CCL2, ↑CCL5, ↑CFLAR, ↓CTSB, ↑CXCL1, ↑CXCL2, ↓GAPDH, ↓HSP90AA1, ↓HSP90B1, ↑ IL1B, ↑IRAK1, ↓MAP3K7, ↓MAPK1, ↓MAPK3, ↓NAIP, ↑P2RX7, ↓PEA15, ↓PYCARD, ↓TAB2, ↑TNF, ↓TNFS14, ↓TRAF6 | 24 | 1.48E-12–2.60E-04 |
| 1a.Cell death of myeloid/phagoCytes | ↓CASP4, ↑CCL2, ↑CCL5, ↑CFLAR, ↑CXCL1, ↑CXCL2, ↑ IL1B, ↑P2RX7, ↓PYCARD, ↑TNF | 10 | 1.72E-12 |
| 2) Inflammation/infectious disease | ↓CASP4, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓HSP90AA1, ↑ IL1B, ↓MAPK1, ↓PANX1, ↑P2RX7, ↓PYCARD, ↑TNF, ↓TNFS14, ↓TRAF6 | 14 | 1.08E-06 |
| 2a. Activation of leukoCyte/lymphoCytes | ↑CCL2, ↑CCL5, ↑CXCL1, ↓HSP90B1, ↓IL1B, ↓MAP3K7, ↓PYCARD, ↑TNF, ↓TNFS14 | 9 | 2.95E-07 |
| 2b. Migration of phagoCytes/neutrophils | ↑CCL2, ↑CCL5, ↓CTSB,↑CXCL1, ↑CXCL2, ↑IL1B, ↑P2RX7, ↑TNF | 8 | 2. 07E-07 |
|
| |||
| Gene regulation by PPARα | ↓HSP90AA1, ↑IL1B, ↓MAP3K7, ↓MAPK1, ↓MAPK3, ↑TNF, ↓TRAF | 7 | 4.16E-10 |
|
| |||
|
| |||
| 1) Cell death (decreased) | ↓ACTB, ↓B2M, ↓CASP4, ↑CCL2, ↑CCL5, ↓CHUK, ↓CTSB,↑CXCL1, ↑CXCL2,↓GAPDH, ↓HSP90AA1, ↓HS90B1, ↑IRAK1, ↑IRF1, ↓MAP3K7, ↓MAPK1 ↓MAPK12, ↑NFKB1A, ↑P2RX7, ↓PEA15, ↑PTGS2, ↓PYCARD, ↓TAB2, ↑TNF, ↓TNFS14, ↓TRAF6 | 26 | 6.53E-12–4.09E-04 |
| 1a.Cell death of myeloid/phagoCytes | ↓CASP4, ↑CCL2, ↑CCL5, ↑CFLAR, ↑CXCL1, ↑CXCL2, ↑ IL1B, ↑P2RX7, ↓PYCARD, ↑TNF | 10 | 1.48E-12 |
| 2) Inflammation/Infectious disease | ↓ACTB, ↓B2M, ↓CASP4, ↑CCL2, ↑CCL5,↓CHUK, ↓CTSB, ↑CXCL1, ↑CXCL2, ↓HSP90B1, ↑IRAK1 ↓MAP3K7, ↑NFKB1A, ↑PTGS2, ↑P2RX7, ↓PYCARD, ↓TIRAP, ↑TNF, ↓TNFS14, ↓TRAF6 | 21 | 3.33E-10–4.43E-04 |
| 2a. Activation of leukoCyte/lymphoCytes | ↓B2M, ↑CCL2, ↑CCL5, ↑CXCL1, ↑CXCL2, ↓MAP3K7, ↑TNF | 7 | 9.31E-06 |
| 2b. Migration of phagoCytes/neutrophils | ↑CCL2, ↑CCL5, ↓CHUK, ↓CTSB, ↑CXCL1, ↑TNF ↑CXCL2, ↑NFKB1A, ↑P2RX7, ↑PTGS2, ↓TIRAP | 11 | 2.43E-04 |
|
| |||
| Gene regulation by PPARα | ↓CHUK, ↓HSP90AA1, ↓MAP3K7, ↓MAPK1, ↓MAP3K7, ↑NFKB1A, ↑PTGS2, ↑TNF, TRAF6 | 9 | 2.11E-11 |
All differentially expressed proteins identified in THP-1 macrophages infected with T. cruzi for 3 or 18 h (±ATP) (listed in Table 1) were uploaded into Ingenuity Pathway Analysis (IPA) to interpret datasets in the context of biological proCesses and function, and pathway and molecular networks. Presented are the top networks with a p value <0.01 to which maximal number of the differentially expressed proteins identified in chagasic plasma (bolded letters) were assoCiated with. FoCus molecules are the number of differentially expressed plasma proteins assoCiated with an individual network.
Figure 3NLRP3/caspase-1 inflammasome is the major source of IL-1β for parasite control in mφs.
THP-1 mφs were incubated with T. cruzi in the presence or absence of cycloheximide (CHX,), glibenclamide (Glb), Ac-YVAD-CHO, and KCl for 3 h (A) and 18 h (B&C). Macrophages incubated with media alone were used as controls. (A&B) IL-1β release in supernatants was determined by an ELISA. (C) Quantitative PCR analysis of parasite burden in infected macrophages using Tc18SrDNA-specific oligonucleotides.
Figure 4Feedback cycle of NOX2/ROS and IL-1β activation in mφs infected by T. cruzi.
THP-1 mφs were infected with T. cruzi as in Fig. 1, and incubated for 3 h (A,C,E) or 18 h (B,D,F,G) in presence of NOX2 inhibitors (diphenylene iodinium (DPI) or apoCynin), ROS scavenger (N-acetylcysteine (NAC)) or IL-1β antibody. (A–D) NOX2 inhibitors decreased ROS and IL-1β levels in infected mφs. Shown are (A&B) H2DCFDA oxidation by intracellular ROS, resulting in formation of fluorescent DCF by fluorimetry and (C&D) IL-1β release in supernatants determined by an ELISA. (E&F) Treatment with anti-IL-1β antibody decreased the ROS levels in infected mφs. (G) Effect of ROS inhibitors on intracellular parasite burden, as determined by qPCR, in infected mφs.
Figure 5IL-1β signals NF-κB activation and inflammatory cytokine gene expression in infected mφs.
(A) The mRNA levels for IL-1β (panel a), TNFα (panel b) and CXCL1 (panel c) cytokines were measured in T. cruzi-infected THP-1 mφs at 3h and 18h pi by quantitative RT-PCR. (B) RAW 264.7 macrophages were transiently transfected with pGL4.NF-κB-Luc reporter plasmid and pREP7-Rluc plasmid (transfection efficiency control) as described in Materials and Methods. Transfected cells were infected with T. cruzi and incubated in the presence or absence of anti-IL-1β antibody. Mφs incubated with 10 ng/ml recombinant TNF-α for 6 h were used as positive controls. The relative NF-κB transcriptional activity was measured by firefly luciferase activity and normalized to Renilla luciferase activity. The transcriptional activity of NF-κB in normal cells was considered as baseline and valued at 1.
Figure 6ASC-/- mφs are compromised in the IL-1β–ROS–NF-κB pathway for control of T. cruzi.
Bone-marrow-derived macrophages were isolated from matched WT and ASC-/- mice. Primary mφs were infected with T. cruzi and incubated for 3 h or 18 h in the presence or absence of anti-IL-1β Ab or ROS scavengers (as in Figs.1&4). Shown are IL-1β release measured by an ELISA (A&B), mRNA levels for IL-1β and TNF-α by quantitative RT-PCR (C&D) and Tc18SrDNA signal by qPCR (E&F).
Figure 7NLRP3-/- mφs are compromised in IL-1β activation and inflammatory cytokine gene expression, but equipped to control T. cruzi.
Bone marrow-derived macrophages were isolated from matched WT and NLRP3-/- mice. Primary mφs were infected with T. cruzi and incubated for 3 h or 18 h in the presence or absence of anti-IL-1β antibody or ROS scavengers (as in Figs.1&4). Shown are IL-1β release by ELISA (A&B), mRNA level for IL-1β, TNF-α and CXCL1 by quantitative RT-PCR (C&D) and Tc18SrDNA signal by qPCR (E).
Figure 8NLRP3 deficiency is compensated for by increased ROS levels in mφs (± T. cruzi).
Bone marrow-derived primary macrophages isolated from matched WT and NLRP3-/- mice were infected with CFSE-labeled T. cruzi and incubated for 3 h or 18 h in the presence or absence of anti-IL-1β antibody or ROS inhibitors. Shown are the mean fluorescence intensity of CFSE (A) as an indicator of # parasites/cell and mean percentage of CFSE+ mφs (B) as an indicator of parasite uptake efficiency. (C) Fluorescence microscopy of NLRP3-/- (panels a, c, e) and WT (panels b, d, e) mφs infected with CFSE-labeled T. cruzi for 18 h. Shown are representative images of CFSE (green, panels a & b), intracellular ROS-specific DHE fluorescence (panels c & d) and overlay images of a & c and b & d in panels e & f. (D&E) Bar graphs show a quantitative measure of ROS release, measured by an Amplex red assay, in NLRP3-/- and WT mφs.